Simon Planken

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Robert L. Hoffman, Robert S. Kania, Mary A. Brothers et al. · Journal of Medicinal Chemistry · 2020 · 518 citations · Full text

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Max Schreuer, Yanina Jansen, Simon Planken et al. · The Lancet Oncology · 2017 · 179 citations

Single Arm, Advanced Brafv600-mutant Melanoma, Medicine +9

Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors

Sherry Niessen, Melissa M. Dix, Sabrina Barbas et al. · Cell chemical biology · 2017 · 100 citations · Full text

Drug Target, Natural Sciences, Proteome-wide Map +3

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Simon Planken, Douglas C. Behenna, Sajiv K. Nair et al. · Journal of Medicinal Chemistry · 2017 · 89 citations · Full text

Molecular Biology, Wild-type Egfr, Chemical Biology +21

Effective Targeting of Hedgehog Signaling in a Medulloblastoma Model with PF-5274857, a Potent and Selective Smoothened Antagonist That Penetrates the Blood–Brain Barrier

Allison Rohner, Mary E. Spilker, Justine L. Lam et al. · Molecular Cancer Therapeutics · 2011 · 51 citations

Cancer Biology, Tumor Biology, Selective Smoothened Antagonist +17